Addendum to Breast Cancer: Evaluating Tumor Estrogen Receptor Status With Molecular Imaging to Increase Response to Therapy and Patient Outcomes

Grabher, Barbara J.

doi:10.2967/jnmt.120.261889

Cited by 7 publications

(1 citation statement)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 F-FES is a specific tracer for ER, while ER is highly expressed in 70% invasive breast cancer. Therefore, we can diagnose breast cancer by detecting ER [12]. In 2019, Sun Young Chae et al verified the accuracy and safety of 18 F-FES PET/CT in evaluating the status of estrogen receptor in recurrent or metastatic breast cancer [13].…”

Section: The Value Of 18 F-fes Pet/ct In the Diagnosis Of Breast Cancermentioning

confidence: 99%

<sup>18</sup>F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

He,

Pang

2024

JBM

View full text Add to dashboard Cite

Estrogen receptor(ER) is a vital biomarker in the development and development of breast cancer, and its status has great clinical value in clinical treatment strategy, endocrine therapy efficacy prediction, and breast cancer prognosis. By specifically combining 18 F-FES with ER, 18 F-FES PET/CT imaging uses standard uptake value(SUV) to semi-quantitatively reflect the distribution of ER and its biological activity in patients, and assesses the expression of ER in breast cancer patients about primary and metastases before or after treatment, to provide a basis for personalized treatment of breast cancer. In this review, we will review the imaging principles of a new ER detection method 18 F-FES PET/CT, and the research progress in the clinical application of breast cancer, and compare its diagnostic and treatment value with non-specific tumor imaging 18 F-FDG PET/CT in breast cancer.

show abstract

Section: The Value Of 18 F-fes Pet/ct In the Diagnosis Of Breast Cancermentioning

confidence: 99%

<sup>18</sup>F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

He,

Pang

2024

JBM

View full text Add to dashboard Cite

show abstract

Novel Tracers and Radionuclides in PET Imaging

Mason¹,

Gimblet²,

Lapi³

et al. 2021

Radiologic Clinics of North America

View full text Add to dashboard Cite

Molecular Imaging for Estrogen Receptor-Positive Breast Cancer

Goodman¹,

Abel²,

Lawhn-Heath³

et al. 2022

Surgical Oncology Clinics of North America

View full text Add to dashboard Cite

Addendum to Breast Cancer: Evaluating Tumor Estrogen Receptor Status With Molecular Imaging to Increase Response to Therapy and Patient Outcomes

Cited by 7 publications

References 24 publications

<sup>18</sup>F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

<sup>18</sup>F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

Novel Tracers and Radionuclides in PET Imaging

Molecular Imaging for Estrogen Receptor-Positive Breast Cancer

Contact Info

Product

Resources

About

Addendum to Breast Cancer: Evaluating Tumor Estrogen Receptor Status With Molecular Imaging to Increase Response to Therapy and Patient Outcomes

Cited by 7 publications

References 24 publications

&lt;sup&gt;18&lt;/sup&gt;F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

&lt;sup&gt;18&lt;/sup&gt;F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

Novel Tracers and Radionuclides in PET Imaging

Molecular Imaging for Estrogen Receptor-Positive Breast Cancer

Contact Info

Product

Resources

About

<sup>18</sup>F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer

<sup>18</sup>F-FES PET/CT Research Progress in the Diagnosis and Treatment of Breast Cancer